As we look toward 2032, the Polyclonal Antibodies market remains a cornerstone of the global diagnostics and research ecosystem. While monoclonal antibodies often capture headlines for therapeutics, the sensitivity and cost-effectiveness of polyclonal versions ensure their continued releva